Sarepta Therapeutics, Inc. - Common Stock (SRPT)

Sarepta shares are plunging in extended trading Monday after the company reports third-quarter results and provided an update on its ESSENCE study.

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Sarepta stock crashed Monday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

New York, NY – October 23, 2025 – Tradr, a prominent innovator in the Exchange-Traded Fund (ETF) market, has today significantly expanded its product suite with the launch of nine new single-stock 2X leveraged ETFs. This marks Tradr's most extensive collection of such launches to date, pushing its total lineup to 48

The new ETFs include the first-of-their-kind gold and AI plays, giving traders targeted exposure without using margin or complex options.

Funds seek to provide 200% long exposure on a variety of industry leaders

Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.

Investors turned upbeat ahead of Sarepta’s data presentations in Vienna, where the company is expected to share new Duchenne muscular dystrophy results and updates from its broader gene therapy pipeline.

Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant decline marks a notable correction for the biotechnology company, which had seen its stock surge dramatically in the preceding days,

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29, 2025, before market open. This highly anticipated announcement is expected to inject significant volatility into the stock, with analysts

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of

These once high-flying stocks no longer seem to have promising prospects.

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys.